The relationship between glucocerebrosidase mutations and Parkinson disease

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 77-90

  Migdalska Richards, Anna ^a   Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

alpha synuclein; Gaucher disease; glucocerebrosidase 1 (GBA1); lysosome; mitochondria; Parkinson disease

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; GLUCOSYLCERAMIDASE;

AUTOPHAGY; BIOCHEMISTRY; CALCIUM HOMEOSTASIS; CATALYSIS; CELL DIFFERENTIATION; COGNITIVE DEFECT; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM STRESS; ENZYME DEGRADATION; GAUCHER DISEASE; GBA1 GENE; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GLYCOSYLATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYDROLYSIS; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; UBIQUITINATION;

EID: 84991248286     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13385     Document Type: Review

References (125)

1. Aharon-Peretz J., Rosenbaum H. and Gershoni-Baruch R. (2004) Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 351, 1972–1977.
2. Alvarez-Erviti L., Rodriguez-Oroz M. C., Cooper J. M., Caballero C., Ferrer I., Obeso J. A. and Schapira A. H. (2010) Chaperone-mediated autophagy markers in Parkinson disease brains. Arch. Neurol. 67, 1464–1472.
3. Angeli A., Mencacci N. E., Duran R. et al. (2013) Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation. Mov. Disord. 28, 1370–1375.
4. Asselta R., Rimoldi V., Siri C., Cilia R., Guella I., Tesei S., Soldà G., Pezzoli G., Duga S. and Goldwurm S. (2014) Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism Relat. Disord. 20, 1215–1220.
5. Beavan M., McNeill A., Proukakis C., Hughes D. A., Mehta A. and Schapira A. H. (2015) Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol. 72, 201–208.
6. Bembi B., Zambito Marsala S., Sidransky E., Ciana G., Carrozzi M., Zorzon M., Martini C., Gioulis M., Pittis M. G. and Capus L. (2003) Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 61, 99–101.
7. Bendikov-Bar I., Ron I., Filocamo M. and Horowitz M. (2011) Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol. Dis. 46, 4–10.
8. Bendikov-Bar I., Maor G., Filocamo M. and Horowitz M. (2013) Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol. Dis. 50, 141–145.
9. Bennett L. L. and Mohan D. (2013) Gaucher disease and its treatment options. Ann. Pharmacother. 47, 1182–1193.
10. Berg-Fussman A., Grace M. E., Ioannou Y. and Grabowski G. A. (1993) Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J. Biol. Chem. 268, 14861–14866.
11. Bernier V., Lagacé M., Bichet D. G. and Bouvier M. (2004) Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol. Metab. 15, 222–228.
12. Beutler E. (1992) Gaucher disease: new molecular approaches to diagnosis and treatment. Science 256, 794–799.
13. Beutler E. and Grabowski G. A. (2001) Glucosylceramide lipidosis–Gaucher disease, in The metabolic and molecular bases of inherited diseases, 8th edn (Scriver C. R., Beaudet A. L., Sly W. S. and Valle D., eds), pp. 3635–3668. McGraw-Hill, New York.
14. Bras J., Paisan-Ruiz C., Guerreiro R., Ribeiro M. H., Morgadinho A., Januario C., Sidransky E., Oliveira C. and Singleton A. (2009) Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol. Aging 30, 1515–1517.
15. Brockmann K., Srulijes K., Hauser A. K., Schulte C., Csoti I., Gasser T. and Berg D. (2011) GBA-associated PD presents with nonmotor characteristics. Neurology 77, 276–280.
16. Bronstein S., Karpati M. and Peleg L. (2014) An update of Gaucher mutations distribution in the Ashkenazi Jewish population: prevalence and country of origin of the mutation R496H. Isr. Med. Assoc. J. 16, 683–685.
17. Bultron G., Kacena K., Pearson D., Boxer M., Yang R., Sathe S., Pastores G. and Mistry P. K. (2010) The risk of Parkinson's disease in type 1 Gaucher disease. J. Inherit. Metab. Dis. 33, 167–173.
18. Choi J. M., Kim W. C., Lyoo C. H. et al. (2012) Association of mutations in the glucocerebrosidase gene with Parkinson disease in a Korean population. Neurosci. Lett. 514, 12–15.
19. Chu Y., Dodiya H. A., Ebischer P. O., lanow C. W. and Kordower J. H. (2009) Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 35, 385–398.
20. Clark L. N., Ross B. M., Wang Y., Mejia-Santana H., Harris J., Louis E. D., Cote L. J., Andrews H., Fahn S., Waters C., Ford B., Frucht S., Ottman R. and Marder K. (2007) Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurol. 69, 1270–1277.
21. Clark L. N., Kartsaklis L. A., Wolf Gilbert R. et al. (2009) Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch. Neurol. 66, 578–583.
22. Cleeter M. W., Chau K. Y., Gluck C., Mehta A., Hughes D. A., Duchen M., Wood N. W., Hardy J., Mark Cooper J. and Schapira A. H. (2013) Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem. Int. 62, 1–7.
23. Cormand B., Montfort M., Chabas A., Vilageliu L. and Grinberg D. (1997) Genetic fine localization of the beta-glucocerebrosidase (GBA) and prosaposin (PSAP) genes: implications for Gaucher disease. Hum. Genet. 100, 75–79.
24. Cox T. M. and Schofield J. P. (1997) Gaucher’ s disease: clinical features and natural history. Baillieres Clin. Haematol. 10, 657–689.
25. Cullen V., Sardi S. P., Ng J. et al. (2011) Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann. Neurol. 69, 940–953.
26. De Marco E. V., Annesi G., Tarantino P. et al. (2008) Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov. Disord. 23, 460–463.
27. Dehay B., Bové J., Rodríguez-Muela N., Perier C., Recasens A., Boya P. and Vila M. (2010) Pathogenic lysosomal depletion in Parkinson ‘ s disease. J. Neurosci. 30, 12535–12544.
28. Dermentzaki G., Dimitriou E., Xilouri M., Michelakakis H. and Stefanis L. (2013) Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells. PLoS ONE 8, e60674.
29. Dvir H., Harel M., McCarthy A. A., Toker L., Silman I., Futerman A. H. and Sussman J. L. (2003) X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. 4, 704–709.
30. Emelyanov A., Boukina T., Yakimovskii A., Usenko T., Drosdova A., Zakharchuk A., Andoskin P., Dubina M., Schwarzman A. and Pchelina S. (2012) Glucocerebrosidase gene mutations are associated with Parkinson's disease in Russia. Mov. Disord. 27, 158–159.
31. Enquist I. B., Lo Bianco C., Ooka A., Nilsson E., Månsson J. E., Ehinger M., Richter J., Brady R. O., Kirik D. and Karlsson S. (2007) Murine models of acute neuronopathic Gaucher disease. Proc. Natl Acad. Sci. USA 104, 17483–17488.
32. Farfel-Becker T., Vitner E., Dekel H., Leshem N., Enquist I. B., Karlsson S. and Futerman A. H. (2009) No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum. Mol. Genet. 18, 1482–1488.
33. Gan-Or Z., Giladi N., Rozovski U., Shifrin C., Rosner S., Gurevich T., Bar-Shira A. and Orr-Urtreger A. (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70, 2277–2283.
34. Gaucher P. C. E. (1882) De l’ epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie. Academic thesis. Paris, France.
35. Gegg M. E., Burke D., Heales S. J., Cooper J. M., Hardy J., Wood N. W. and Schapira A. H. (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455–463.
36. Gegg M. E., Sweet L., Wang B. H., Shihabuddin L. S., Sardi S. P. and Schapira A. H. V. (2015) No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov. Disord. 30, 1085–1089.
37. Goker-Alpan O., Schiffmann R., Lamarca M. E., Nussbaum R. L., Mcinerney-Leo A. and Sidransky E. (2004) Parkinsonism among Gaucher disease carriers. J. Med. Genet. 41, 937–940.
38. Goker-Alpan O., Lopez G., Vithayathil J., Davis J., Hallett M. and Sidransky E. (2008) The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch. Neurol. 65, 1353–1357.
39. Goker-Alpan O., Stubblefield B. K., Giasson B. I. and Sidransky E. (2010) Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathol. 120, 641–649.
40. Goker-Alpan O., Masdeu J. C., Kohn P. D. et al. (2012) The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain 135, 2440–2448.
41. González-Del Rincón Mde L., Monroy Jaramillo N., Suárez Martínez A. I., Yescas Gómez P., Boll Woehrlen M. C., López López M. and Alonso Vilatela M. E. (2013) The L444P GBA mutation is associated with early-onset Parkinson's disease in Mexican Mestizos. Clin. Genet. 84, 386–387.
42. Grabowski G. A. (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372, 1263–1271.
43. Halperin A., Elstein D. and Zimran A. (2006) Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol. Dis. 36, 426–428.
44. Horowitz M., Wilder S., Horowitz Z., Reiner O., Gelbart T. and Beutler E. (1989) The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 4, 87–96.
45. Hruska K. S., LaMarca M. E., Scott C. R. and Sidransky E. (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 29, 567–583.
46. Hu F. Y., Xi J., Guo J., Yu L. H., Liu L., He X. H., Liu Z. L., Zou X. Y. and Xu Y. M. (2010) Association of the glucocerebrosidase N370S allele with Parkinson's disease in two separate Chinese Han populations of mainland China. Eur. J. Neurol. 17, 1476–1478.
47. Huang C. L., Wu-Chou Y. H., Lai S. C., Chang H. C., Yeh T. H., Weng Y. H., Chen R. S., Huang Y. Z. and Lu C. S. (2011) Contribution of glucocerebrosidase mutation in a large cohort of sporadic Parkinson's disease in Taiwan. Eur. J. Neurol. 18, 1227–1232.
48. Imai Y., Soda M. and Takahashi R. (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 205, 35661–35664.
49. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y. and Takahashi R. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891–902.
50. Jovic M., Kean M. J., Szentpetery Z., Polevoy G., Gingras A. C., Brill J. A. and Balla T. (2012) Two phosphatidylinositol 4-kinases control lysosomal delivery of the Gaucher disease enzyme, beta-glucocerebrosidase. Mol. Biol. Cell 23, 1533–1545.
51. Kalinderi K., Bostantjopoulou S., Paisan-Ruiz C., Katsarou Z., Hardy J. and Fidani L. (2009) Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci. Lett. 452, 87–89.
52. Kumar K. R., Ramirez A., Göbel A. et al. (2013) Glucocerebrosidase mutations in a Serbian Parkinson's disease population. Eur. J. Neurol. 20, 402–405.
53. Lesage S. and Brice A. (2009) Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18, R48–R59.
54. Lesage S., Anheim M., Condroyer C. et al. French Parkinson's Disease Genetics Study Group (2011) Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum. Mol. Genet. 20, 202–210.
55. Luan Z., Li L., Higaki K., Nanba E., Suzuki Y. and Ohno K. (2013) The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice. Brain Dev. 35, 317–322.
56. Lwin A., Orvisky E., Goker-Alpan O., Lamarca M. E. and Sidransky E. (2004) Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab. 81, 70–73.
57. Maegawa G. H., Tropak M. B., Buttner J. D. et al. (2009) Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 284, 23502–23516.
58. Manning-Boğ A. B., Schüle B. and Langston J. W. (2009) Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 30, 1127–1132.
59. Mao X. Y., Burgunder J. M., Zhang Z. J., An X. K., Zhang J. H., Yang Y., Li T., Wang Y. C., Chang X. L. and Peng R. (2010) Association between GBA L444P mutation and sporadic Parkinson's disease from Mainland China. Neurosci. Lett. 469, 256–259.
60. Mata I. F., Samii A., Schneer S. H. et al. (2008) Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch. Neurol. 65, 379–382.
61. Mazzulli J. R., Xu Y. H., Sun Y., Knight A. L., McLean P. J., Caldwell G. A., Sidransky E., Grabowski G. A. and Krainc D. (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37–52.
62. McKeran R. O., Bradbury P., Taylor D. and Stern G. (1985) Neurological involvement of type 1 (adult) Gaucher's disease. J. Neurol. Neurosurg. Psychiatry 48, 172–175.
63. McNeill A., Duran R., Hughes D. A., Mehta A. and Schapira A. H. (2012a) A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. J. Neurol. Neurosurg. Psychiatry 83, 853–854.
64. McNeill A., Duran R., Proukakis C., Bras J., Hughes D., Mehta A., Hardy J., Wood N. W. and Schapira A. H. (2012b) Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov. Disord. 27, 526–532.
65. McNeill A., Roberti G., Lascaratos G., Hughes D., Mehta A., Garway-Heath D. F. and Schapira A. H. (2013a) Retinal thinning in Gaucher disease patients and carriers: results of a pilot study. Mol. Genet. Metab. 109, 221–223.
66. McNeill A., Wu R. M., Tzen K. Y. et al. (2013b) Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. PLoS ONE 8, e69190.
67. McNeill A., Magalhaes J., Shen C. et al. (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137, 1481–1495.
68. Moraitou M., Hadjigeorgiou G., Monopolis I. et al. (2011) β-glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. Mol. Genet. Metab. 104, 149–152.
69. National Organization of Rare Disorders (2013) Gaucher disease. http://www.rarediseases.org/rare-disease-information/rarediseases/byID/12/viewFullReport. [accessed on July 25, 2013].
70. Neumann J., Bras J., Deas E. et al. (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132, 1783–1794.
71. Osellame L. D., Rahim A. A., Hargreaves I. P., Gegg M. E., Richard-Londt A., Brandner S., Waddington S. N., Schapira A. H. and Duchen M. R. (2013) Mitochondria and quality control defects in a mouse model of Gaucher disease — links to Parkinson's disease. Cell Metab. 17, 941–953.
72. Patnaik S., Zheng W., Choi J. H. et al. (2012) Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J. Med. Chem. 55, 5734–5748.
73. Pulkes T., Choubtum L., Chitphuk S., Thakkinstian A., Pongpakdee S., Kulkantrakorn K., Hanchaiphiboolkul S., Tiamkao S. and Boonkongchuen P. (2014) Glucocerebrosidase mutations in Thai patients with Parkinson's disease. Parkinsonism Relat. Disord. 20, 986–991.
74. Reczek D., Schwake M., Schroder J., Hughes H., Blanz J., Jin X., Brondyk W., Van Patten S., Edmunds T. and Saftig P. (2007) LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 131, 770–783.
75. Richter F., Fleming S. M., Watson M. et al. (2014) A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics 11, 840–856.
76. Rocha E. M., Smith G. A., Park E., Cao H., Brown E., Hallett P. and Isacson O. (2015) Progressive decline of glucocerebrosidase in aging and Parkinson's disease. Ann. Clin. Transl. Neurol. 2, 433–438.
77. Ron I. and Horowitz M. (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 14, 2387–2398.
78. Ron I., Rapaport D. and Horowitz M. (2010) Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Hum. Mol. Genet. 19, 3771–3781.
79. Ryu E. J., Harding H. P., Angelastro J. M., Vitolo O. V., Ron D. and Greene L. A. (2002) Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J. Neurosci. 22, 10690–10698.
80. Sanders A., Hemmelgarn H., Melrose H. L., Hein L., Fuller M. and Clarke L. A. (2013) Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease. Blood Cells Mol. Dis. 51, 109–115.
81. Sardi S. P., Clarke J., Viel C. et al. (2013) Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other gaucher-related synucleinopathies. Proc. Natl Acad. Sci. USA 110, 3537–3542.
82. Sato C., Morgan A., Lang A. E., Salehi-Rad S., Kawarai T., Meng Y., Ray P. N., Farrer L. A., St George-Hyslop P. and Rogaeva E. (2005) Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov. Disord. 20, 367–370.
83. Sawkar A. R., Cheng W. C., Beutler E., Wong C. H., Balch W. E. and Kelly J. W. (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl Acad. Sci. USA 99, 15428–15433.
84. Schapira A. H. (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7, 97–109.
85. Schapira A. H. and Gegg M. E. (2013) Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc. Natl Acad. Sci. USA 110, 3214–3215.
86. Schapira A. H. and Tolosa E. (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol. 6, 309–317.
87. Schapira A. H., Cooper J. M., Dexter D., Jenner P., Clark J. B. and Marsden C. D. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269.
88. Schapira A. H., Cooper J. M., Dexter D., Clark J. B., Jenner P. and Marsden C. D. (1990) Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823–827.
89. Setó-Salvia N., Pagonabarraga J., Houlden H. et al. (2012) Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov. Disord. 27, 393–399.
90. Sidransky E. (2012) Gaucher disease: insights from a rare Mendelian disorder. Discov. Med. 14, 273–281.
91. Sidransky E. and Lopez G. (2012) The link between the GBA gene and parkinsonism. Lancet Neurol. 11, 986–998.
92. Sidransky E., Nalls M. A., Aasly J. O. et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651–1661.
93. Sorge J., West C., Westwood B. and Beutler E. (1985) Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. Proc. Natl Acad. Sci. USA 82, 7289–7293.
94. Sorge J., Kuhl W., West C. and Beutler E. (1987a) Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer. Proc. Natl Acad. Sci. USA 84, 906–909.
95. Sorge J. A., West C., Kuhl W., Treger L. and Beutler E. (1987b) The human glucocerebrosidase gene has two functional ATG initiator codons. Am. J. Hum. Genet. 41, 1016–1024.
96. Sorge J., Gross E., West C. and Beutler E. (1990) High level transcription of the glucocerebrosidase pseudogene in normal subjects and patients with Gaucher disease. J. Clin. Invest. 86, 1137–1141.
97. Spitz M., Rozenberg R., Pereira Lda. V. and Reis Barbosa E. (2008) Association between Parkinson's disease and glucocerebrosidase mutations in Brazil. Parkinsonism Relat. Disord. 14, 58–62.
98. Steet R. A., Chung S., Wustman B., Powe A., Do H. and Kornfeld S. A. (2006) The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc. Natl Acad. Sci. USA 103, 13813–13818.
99. Stone D. L., Tayebi N., Orvisky E., Stubblefield B., Madike V. and Sidransky E. (2000) Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum. Mutat. 15, 181–188.
100. Sun Q. Y., Guo J. F., Wang L., Yu R. H., Zuo X., Yao L. Y., Pan Q., Xia K. and Tang B. S. (2010a) Glucocerebrosidase gene L444P mutation is a risk factor for Parkinson's disease in Chinese population. Mov. Disord. 25, 1005–1011.
101. Sun Y., Liou B., Ran H. et al. (2010b) Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum. Mol. Genet. 19, 1088–1097.
102. Suzuki Y., Ogawa S. and Sakakibara Y. (2009) Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspect. Medicin. Chem. 3, 7–19.
103. Swan M. and Saunders-Pullman R. (2013) The association between ß-glucocerebrosidase mutations and parkinsonism. Curr. Neurol. Neurosci. Rep. 13, 368.
104. Tamboli I. Y., Hampel H., Tien N. T., Tolksdorf K., Breiden B., Mathews P. M., Saftig P., Sandhoff K. and Walter J. (2011) Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation. J. Neurosci. 31, 1837–1849.
105. Tan E. K., Tong J., Fook-Chong S., Yih Y., Wong M. C., Pavanni R. and Zhao Y. (2007) Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch. Neurol. 64, 1056–1058.
106. Tayebi N., Cushner S. and Sidransky E. (1996) Differentiation of the glucocerebrosidase gene from pseudogene by long-template PCR: implications for Gaucher disease. Am. J. Hum. Genet. 59, 740–741.
107. Tayebi N., Callahan M., Madike V., Stubblefield B. K., Orvisky E., Krasnewich D., Fillano J. J. and Sidransky E. (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol. Genet. Metab. 73, 313–321.
108. Tayebi N., Walker J., Stubblefield B., Orvisky E., Lamarca M. E., Wong K., Rosenbaum H., Schiffmann R., Bembi B. and Sidransky E. (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol. Genet. Metab. 79, 104–109.
109. Toft M., Pielsticker L., Ross O. A., Aasly J. O. and Farrer M. J. (2006) Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 66, 415–417.
110. Turpin J. C., Dubois G., Brice A., Masson M., Nadaud M. C., Boutry J. M., Schram A. W., Tager J. M. and Baumann N. (1988) Parkinsonian symptomatology in a patient with type I (adult) Gaucher's disease. Lipid Storage Disord. NATO ASI Ser. 150, 103–105.
111. Vaccaro A. M., Motta M., Tatti M., Scarpa S., Masuelli L., Bhat M., Vanier M. T., Tylki-Szymanska A. and Salvioli R. (2010) Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting. Hum. Mol. Genet. 19, 2987–2997.
112. Varkonyi J., Rosenbaum H., Baumann N., Mackenzie J. J., Simon Z., Aharon-Peretz J., Walker J. M., Tayebi N. and Sidransky E. (2003) Gaucher disease associated with parkinsonism: four further case reports. Am. J. Med. Genet. A 116A, 348–351.
113. Vila M., Bové J., Dehay B., Rodríguez-Muela N. and Boya P. (2011) Lysosomal membrane permeabilization in Parkinson disease. Autophagy 7, 98–100.
114. Wang Y., Liu L., Xiong J. et al. (2012) Glucocerebrosidase L444P mutation confers genetic risk for Parkinson's disease in central China. Behav. Brain Funct. 1, 8–57.
115. Westbroek W., Gustafson A. M. and Sidransky E. (2011) Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol. Med. 17, 485–493.
116. Winder-Rhodes S. E., Evans J. R., Ban M., Mason S. L., Williams-Gray C. H., Foltynie T., Duran R., Mencacci N. E., Sawcer S. J. and Barker R. A. (2013) Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 136, 392–399.
117. Wu Y. R., Chen C. M., Chao C. Y., Ro L. S., Lyu R. K., Chang K. H. and Lee-Chen G. J. (2007) Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J. Neurol. Neurosurg. Psychiatry 78, 977–979.
118. Xilouri M., Vogiatzi T., Vekrellis K., Park D. and Stefanis L. (2009) Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 4, e5515.
119. Xu Y. H., Xu K., Sun Y. et al. (2014) Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum. Mol. Genet. 23, 3943–3957.
120. Yap T. L., Gruschus J. M., Velayati A., Westbroek W., Goldin E., Moaven N., Sidransky E. and Lee J. C. (2011) Alpha-synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J. Biol. Chem. 286, 28080–28088.
121. Yoshida H. (2007) ER stress and diseases. FEBS J. 274, 630–658.
122. Yu Z., Wang T., Xu J. et al. (2015) Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinson's disease. J. Hum. Genet. 60, 85–90.
123. Zhang X., Bao Q. Q., Zhuang X. S. et al. (2012) Association of common variants in the glucocerebrosidase gene with high susceptibility to Parkinson's disease among Chinese. Chin. J. Physiol. 55, 398–404.
124. Ziegler S. G., Eblan M. J., Gutti U., Hruska K. S., Stubblefield B. K., Goker-Alpan O., LaMarca M. E. and Sidransky E. (2007) Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol. Genet. Metab. 91, 195–200.
125. Zokaei N., McNeill A., Proukakis C. et al. (2014) Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. Brain 137(Pt 8), 2303–2311.